Darzalex (daratumumab) Dosage Details: Forms, Strengths, Usage, and Additional Information
Darzalex, a brand-name prescription infusion, is used to treat multiple myeloma in adults. This medication contains the active ingredient daratumumab, a biologic that belongs to a class of drugs called monoclonal antibodies.
The Food and Drug Administration (FDA) has approved Darzalex for treating multiple myeloma in adults who have had previous treatments or are ineligible for autologous stem cell transplant (ASCT).
Darzalex is given as an intravenous (IV) infusion by a healthcare professional. It comes as a solution in a single-dose vial, and the typical dosage for most of its approved uses is 16 milligrams per kilogram (mg/kg) of body weight.
For adults who have had previous treatments, the recommended dose of Darzalex is 16 mg/kg of body weight. In the induction phase of treatment, Darzalex is administered weekly (once per week) for 8 doses. In the intermediate phase, the medication is given every two weeks (days 1 and 15 of the cycle) for 8 doses. During the maintenance phase, Darzalex is administered every four weeks (day 1 of each cycle).
In a combination therapy with lenalidomide and dexamethasone, Darzalex follows a 28-day cycle regimen. The induction phase (weeks 1–8/cycles 1–2) involves Daratumumab being administered weekly for 8 doses. The intermediate phase (weeks 9–24/cycles 3–6) consists of Daratumumab being given every two weeks for 8 doses. The maintenance phase (week 25 and beyond/cycle 7+) involves Daratumumab being administered every four weeks. Lenalidomide and dexamethasone are given continuously in 28-day cycles alongside Darzalemumab.
Missing a Darzalex infusion appointment should be reported to the doctor as soon as possible. A medication reminder can be used to help avoid missing appointments. It is essential to remember that Darzalex is a long-term treatment and is meant to be taken long-term if it is safe and effective.
There is no generic form of Darzalex, and the dosage of Darzalemumab can be affected by previous treatments for multiple myeloma, ASCT, other medications, body weight, and other medical conditions. Certain reactions during treatment with Darzalex may require the infusion to be stopped or slowed down.
This combination therapy (Daratumumab + Lenalidomide + Dexamethasone) has become a standard of care for relapsed/refractory patients ineligible for transplant or insufficiently responsive to prior therapy. The dose of daratumumab is typically 16 mg/kg intravenously per infusion, adjusted to clinical protocols.
References:
- Medical Coverage Guidelines (2025) — Daratumumab (Darzalex) dosing schedule with lenalidomide and dexamethasone, including induction, consolidation, and maintenance phases.
- Recent clinical trials confirm lenalidomide-dexamethasone doses in 28-day cycles compatible with daratumumab triplet use in transplant-ineligible myeloma patients.
- Despite Darzalex primarily being used for multiple myeloma, it's crucial to remember that other cancers may also require different therapies and treatments.
- Science continues to evolve, and novel treatments like Darzalex, a monoclonal antibody, are contributing significantly to the health and wellness of people living with medical conditions such as multiple myeloma.
- In addition to Darzalex, other medications, body weight, ASCT, and other medical conditions can affect the dosage of daratumumab, necessitating careful consideration by healthcare professionals during the course of treatment.
%20Dosage%20Details%3A%20Forms%2C%20Strengths%2C%20Usage%2C%20and%20Additional%20Information){kind=link}